Css LLC Chemo Centryx, Inc. Call Options Transaction History

Css LLC

$999 Million
Q3 2024

Call Options

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $168,872 - $297,312	-7,600 Reduced 95.0%	400 $10,000
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $578,970 - $1.28 Million	-31,500 Reduced 79.75%	8,000 $291,000
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $776,302 - $1.17 Million	-58,900 Reduced 59.86%	39,500 $676,000
Q2 2021 Aug 16, 2021	BUY	$9.59 - $50.88 $943,656 - $5.01 Million	98,400 New	98,400 $1.32 Million
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $302,133 - $417,240	-6,100 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $132,300 - $182,448	-2,800 Reduced 31.46%	6,100 $378,000
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $4.8 Million - $6.39 Million	-103,600 Reduced 92.09%	8,900 $488,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $4.34 Million - $7.32 Million	112,500 New	112,500 $6.47 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.